BR112018009899A8 - composição, inalador, forma de dosagem única, métodos para fabricar partículas, para melhorar as exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para prevenir as exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para reduzir a incidência das exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para reduzir a gravidade das exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para prevenir uma infecção respiratória viral e para fabricar uma partícula de inalação de pó seco de ribavirina controlada na forma polimorfa cristalina, partículas fabricadas, método de tratamento, pluralidade de partículas, e, recipiente de dose. - Google Patents

composição, inalador, forma de dosagem única, métodos para fabricar partículas, para melhorar as exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para prevenir as exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para reduzir a incidência das exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para reduzir a gravidade das exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para prevenir uma infecção respiratória viral e para fabricar uma partícula de inalação de pó seco de ribavirina controlada na forma polimorfa cristalina, partículas fabricadas, método de tratamento, pluralidade de partículas, e, recipiente de dose.

Info

Publication number
BR112018009899A8
BR112018009899A8 BR112018009899A BR112018009899A BR112018009899A8 BR 112018009899 A8 BR112018009899 A8 BR 112018009899A8 BR 112018009899 A BR112018009899 A BR 112018009899A BR 112018009899 A BR112018009899 A BR 112018009899A BR 112018009899 A8 BR112018009899 A8 BR 112018009899A8
Authority
BR
Brazil
Prior art keywords
respiratory
respiratory infection
infection
induced exacerbations
disorder
Prior art date
Application number
BR112018009899A
Other languages
English (en)
Other versions
BR112018009899A2 (pt
Inventor
T Farrer Brian
D Roberts Christopher
J Sprague Jacob
Robert Savage John
Charles Dell'orco Philip
Wang Yongcai
Hong Zhi
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Liquidia Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd, Liquidia Tech Inc filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112018009899A2 publication Critical patent/BR112018009899A2/pt
Publication of BR112018009899A8 publication Critical patent/BR112018009899A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

são divulgadas as composições farmacêuticas antivirais inaláveis de ribavirina, os métodos de produzir as mesmas, e o uso de tais composições no tratamento de infecções respiratórias viralmente associadas, e doenças e condições associadas.
BR112018009899A 2015-11-18 2016-11-18 composição, inalador, forma de dosagem única, métodos para fabricar partículas, para melhorar as exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para prevenir as exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para reduzir a incidência das exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para reduzir a gravidade das exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para prevenir uma infecção respiratória viral e para fabricar uma partícula de inalação de pó seco de ribavirina controlada na forma polimorfa cristalina, partículas fabricadas, método de tratamento, pluralidade de partículas, e, recipiente de dose. BR112018009899A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562256868P 2015-11-18 2015-11-18
PCT/IB2016/056981 WO2017085692A1 (en) 2015-11-18 2016-11-18 Pharmaceutical compositions of ribavirin

Publications (2)

Publication Number Publication Date
BR112018009899A2 BR112018009899A2 (pt) 2018-11-06
BR112018009899A8 true BR112018009899A8 (pt) 2019-02-26

Family

ID=57442758

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009899A BR112018009899A8 (pt) 2015-11-18 2016-11-18 composição, inalador, forma de dosagem única, métodos para fabricar partículas, para melhorar as exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para prevenir as exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para reduzir a incidência das exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para reduzir a gravidade das exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para prevenir uma infecção respiratória viral e para fabricar uma partícula de inalação de pó seco de ribavirina controlada na forma polimorfa cristalina, partículas fabricadas, método de tratamento, pluralidade de partículas, e, recipiente de dose.

Country Status (10)

Country Link
US (1) US20210315915A1 (pt)
EP (1) EP3377045A1 (pt)
JP (1) JP2018535984A (pt)
KR (1) KR20180080328A (pt)
CN (1) CN108348470A (pt)
AU (1) AU2016357651A1 (pt)
BR (1) BR112018009899A8 (pt)
CA (1) CA3004492A1 (pt)
RU (1) RU2018120519A (pt)
WO (1) WO2017085692A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11446244B2 (en) 2020-01-17 2022-09-20 Matthew McLeay Compositions containing verteporfin, ribavirin, gemcitabine, or combinations thereof and methods of use for treating COVID-19, cancer, or non cancer diseases
US20230241037A1 (en) * 2020-03-09 2023-08-03 1Globe Health Institute, Nanjing Cross-linked medication for treatment of coronaviral infection and method of treatment
CN111297838A (zh) * 2020-04-08 2020-06-19 宁波合康生物医药科技有限公司 一种抗病毒药物的吸入喷雾剂
EP4138832A1 (en) * 2020-04-24 2023-03-01 Topelia Aust Limited Products of manufacture and methods for treating, ameliorating or preventing microbial infections
IT202100002003A1 (it) * 2021-02-01 2022-08-01 Plumestars S R L Nuove composizioni antivirali e loro utilizzo in terapia e nel trattamento di infezioni virali

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
NL192564C (nl) 1982-10-08 1997-10-03 Glaxo Group Ltd Inrichting voor het toedienen van medicamenten aan patiënten.
PT83094B (pt) 1985-07-30 1993-07-30 Glaxo Group Ltd Dispositivos proprios para a administracao de medicamentos a pacientes
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE69413955T2 (de) 1993-03-17 1999-04-01 Minnesota Mining & Mfg Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel
ES2179192T3 (es) 1995-04-14 2003-01-16 Smithkline Beecham Corp Inhibidor dosificador para albuterol.
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6453758B1 (en) 1999-06-11 2002-09-24 Msp Corporation Efficient high-productivity cascade impactors
US6543301B2 (en) 2000-12-08 2003-04-08 Msp Corporation Impactor nozzle plate
US6595368B2 (en) 2000-12-08 2003-07-22 Msp Corporation Pre-separator for inlets of cascade impactors
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
CN1304010C (zh) * 2003-04-28 2007-03-14 南昌弘益科技有限公司 利巴韦林吸入粉雾剂及其制备工艺
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
CA2847260C (en) 2003-12-19 2016-06-21 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
WO2007021762A2 (en) 2005-08-09 2007-02-22 The University Of North Carolina At Chapel Hill Methods and materials for fabricating microfluidic devices
CN101442989B (zh) * 2004-06-21 2013-04-03 诺瓦帝斯公司 包括两性霉素b的组合物
WO2006060027A2 (en) * 2004-09-20 2006-06-08 Corus Pharma, Inc. A method for improvement of tolerance for therapeutically effective agents delivered by inhalation
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
US8944804B2 (en) 2006-01-04 2015-02-03 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
WO2008013952A2 (en) 2006-07-27 2008-01-31 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
JP5604301B2 (ja) 2007-10-12 2014-10-08 リクイディア・テクノロジーズ・インコーポレーテッド 粒子およびパターン化フィルムを製造するためのシステムおよび方法
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
WO2009143011A1 (en) 2008-05-20 2009-11-26 Novartis Ag Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
WO2010065748A2 (en) 2008-12-05 2010-06-10 Liquidia Technologies, Inc. Method for producing patterned materials
US20120114554A1 (en) 2009-07-13 2012-05-10 Liquidia Technologies, Inc. Engineered Aerosol Particles, And Associated Methods
CN106551909A (zh) * 2015-09-23 2017-04-05 苏州欧米尼医药有限公司 一种高分散微细粉体颗粒的制备方法

Also Published As

Publication number Publication date
WO2017085692A1 (en) 2017-05-26
EP3377045A1 (en) 2018-09-26
KR20180080328A (ko) 2018-07-11
US20210315915A1 (en) 2021-10-14
RU2018120519A (ru) 2019-12-18
CA3004492A1 (en) 2017-05-26
JP2018535984A (ja) 2018-12-06
BR112018009899A2 (pt) 2018-11-06
AU2016357651A1 (en) 2018-05-17
CN108348470A (zh) 2018-07-31

Similar Documents

Publication Publication Date Title
BR112018009899A2 (pt) composição, inalador, forma de dosagem única, métodos para fabricar partículas, para melhorar as exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para prevenir as exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para reduzir a incidência das exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para reduzir a gravidade das exacerbações induzidas por infecção respiratória de um distúrbio respiratório, para prevenir uma infecção respiratória viral e para fabricar uma partícula de inalação de pó seco de ribavirina controlada na forma polimorfa cristalina, partículas fabricadas, método de tratamento, pluralidade de partículas, e, recipiente de dose.
BR112016022598A8 (pt) composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso
BR112017016006A2 (pt) composto, composição farmacêutica, método de tratamento de doenças e condições, uso de um composto e de uma combinação, e, combinação.
IL230458A (en) Annotated 2-Methylbenzamidazole is converted into heterocycles, containing pharmaceuticals and used in the preparation of drugs for the treatment and prevention of syncytial respiratory disease
IL246117A0 (en) Administration, use and therapeutic applications of crispr-cas systems and preparations for HBV and viral diseases and disorders
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
JP2016006053A5 (pt)
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
NZ701647A (en) Compounds and methods for antiviral treatment
BR112017018977A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de uma infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, em um hospedeiro em necessidade do mesmo e para fabricação de um medicamento direcionado para uso terapêutico para tratamento de uma infecção pelo vírus da hepatite c, uso de um composto, e, formulação farmacêutica?.
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
UY37328A (es) Compuestos diazaheterobicíclicos sustituidos y su uso
IL230874A (en) History of dihydroquinoline-2-on-egg scallops, their preparation process, pharmaceutical preparations containing them and their use in the preparation of drugs
BR112017001565A2 (pt) ?composto, métodos para tratar uma infecção e para fabricar um medicamento, composição farmacêutica, e, uso de um composto?
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
JP2015044878A5 (pt)
WO2015044961A3 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
EA201990834A1 (ru) Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
CY1120749T1 (el) Φαρμακευτικες δοσολογικες μορφες
BR112019014738A8 (pt) Composto, forma de dosagem sólida, composição farmacêutica, forma cristalina de composto, método para tratar infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, composto da fórmula, e, uso de um composto da fórmula
FR3072821B1 (fr) Procede de l’observance par la preparation des doses a administrer des medicaments

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]